GlaxoSmithKline Pharmaceuticals
GlaxoSmithKline Pharmaceuticals Ltd, operating as GSK India, is an Indian pharmaceutical enterprise manufacturing and marketing prescription drugs and vaccines across India. Operating as a subsidiary of the global GSK group, the company formulates, packages, and distributes prescription pharmaceuticals targeting dermatology, anti-infectives, respiratory diseases, oncology, and pediatric vaccines like Infanrix and Synflorix. Principal revenues derive from wholesale pharmaceutical product sales directly to medical distributors, hospital networks, and retail pharmacy chains across India. Core end markets encompass prescription patients, pediatric clinics, clinical hospital networks, and retail pharmacies throughout India. GSK India holds a market-leading position in the Indian pharmaceutical industry for pediatric vaccines and prescription anti-infectives. The company is headquartered in Mumbai, India, and its equity shares trade on the BSE and National Stock Exchange of India.
5 of the funds FundTelligence covers report a position in GlaxoSmithKline Pharmaceuticals.
- Legal name
- GlaxoSmithKline Pharmaceuticals Ltd
- Sector
- Health Care
- Country
- India
- Funds holding it
- 5
Funds holding GlaxoSmithKline Pharmaceuticals
- SEB Asienfond ex Japan — SEB · 0.08 % (full portfolio disclosed, June 2026)
- Handelsbanken Emerging Markets Index — Handelsbanken · 0.02 % (full portfolio disclosed, September 2026)
- SEB Emerging Marketsfond — SEB · 0.02 % (full portfolio disclosed, June 2026)
- Handelsbanken Global Index Criteria — Handelsbanken · 0.01 % (full portfolio disclosed, September 2026)
- BlackRock iShares MSCI EM IMI Screened UCITS ETF — BlackRock · 0.01 % (full portfolio disclosed, October 2026)